7 completed, 1 terminated. 8 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Completed 7, Terminated 1 |
Follow Filariasis: new trials by email Literature Review of Filariasis trials Research Report on Filariasis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Learn About How Much Emodepside Gets Absorbed in the Blood and How Food Affects Its Absorption When Given as a New Type of Tablet to Healthy Participants BAY 44-4400 - Soil-transmitted Helminth Infection, Onchocerciasis (River Blindness) | Phase 1 | Completed | Bayer | 14 | 2024-05-07 | 2024-09-27 |
| PK, Safety and Tolerability of Single and Multiple Doses of Oxfendazole Tablets Oxfendazole, Placebo - Filariasis | Phase 1 | Completed | Swiss Tropical & Public Health Institute | 30 | 2022-04-21 | 2022-12-20 |
| Development of AWZ1066S, a Small Molecule Anti-Wolbachia Candidate Macrofilaricide Drug AWZ1066S, Placebo - Filariasis, Lymphatic, Onchocerciasis | Phase 1 | Terminated | Liverpool School of Tropical Medicine | 30 | 2021-12-10 | 2023-09-21 |
| A Pharmacokinetic and Safety Study of Moxidectin to Identify an Optimal Dose for Treatment of Children 4 to 11 Years Moxidectin - Onchocerciasis | Phase 1 | Completed | Medicines Development for Global Health | 36 | 2021-03-29 | 2025-09-05 |
| Safety, Tolerability and PK of Multiple-ascending Doses of Emodepside LSF emodepside (BAY 44-4400) or matching placebo - Filariasis | Phase 1 | Completed | Drugs for Neglected Diseases | 24 | 2017-11-14 | 2020-04-15 |
| Relative Bioavailability Study of Emodepside IR-tablets and Solution Emodepside (BAY 44-4400) - Filariasis | Phase 1 | Completed | Drugs for Neglected Diseases | 77 | 2017-10-26 | 2020-03-09 |
| Pharmacokinetics & Pharmacodynamics of Diethylcarbamazine (DEC)+ Albendazole (ALB) + Ivermectin (IVE) Ivermectin, Diethylcarbamazine Albendazole (IDA) - Wuchereria Bancrofti Infection | Phase 1 | Completed | University Hospitals Cleveland Medical Center | 66 | 2016-04-17 | 2019-04-26 |
| First in Man Clinical Trial of Emodepside (BAY 44-4400) emodepside (BAY 44-4400), placebo - Healthy Volunteers | Phase 1 | Completed | Drugs for Neglected Diseases | 79 | 2015-12-01 | 2020-04-13 |
Onchocerciasis (5) · Elephantiasis, Filarial (2) · Neglected Diseases (2) · Parasitic Diseases (2) · Helminthiasis (1) · Nematode Infections (1) · Onchocerciasis, Ocular (1) · Secernentea Infections (1) · Skin Diseases (1) · Skin Diseases, Infectious (1) · Skin Diseases, Parasitic (1) · Skin and Connective Tissue Diseases (1) · Spirurida Infections (1)
Infections (8) · Helminthiasis (7) · Nematode Infections (7) · Secernentea Infections (7) · Spirurida Infections (7) · Parasitic Diseases (6) · Skin Diseases (4) · Skin Diseases, Infectious (4) · Skin Diseases, Parasitic (4) · Skin and Connective Tissue Diseases (4) · Vector Borne Diseases (3) · Disease Attributes (2) · Hemic and Lymphatic Diseases (2) · Lymphatic Diseases (2)
Bay 44-4400 (4) · emodepside (2) · Ivermectin (1) · Praziquantel (1) · moxidectin (1) · oxfendazole (1) · toltrazuril (1)
Drugs for Neglected Diseases (3) · Bayer (1) · Liverpool School of Tropical Medicine (1) · Medicines Development for Global Health (1) · Swiss Tropical & Public Health Institute (1) · University Hospitals Cleveland Medical Center (1)
United Kingdom (4) · Côte d’Ivoire (1) · Germany (1) · Ghana (1) · Tanzania (1)
Daniel Paris (1) · Frederic Monnot (1) · Graham Devereux, MD (1) · Jeremy Dennison (1) · Jeremy Dennison, PhD MBChB (1) · Malcolm Boyce, MD, BSc (1) · Nicholas O Opoku, MD (1) · Said Jongo (1)
PMID 31107869, PMID 34310218, PMID 37262040, PMID 38924387, PMID 40707999, PMID 41121745, PMID 41662151, PMID 41705834, PMID 42848323
2017 (2), 2015 (1), 2023 (1)